Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLixia ShengWWWinston Duo WuYZYi Zhang

Discussion

Loading...

Member takes

Overview

Observational analysis improved progression-free survival in large B-cell lymphoma, indicating a promising CAR-T approach combining PD-1 blockade and armoring strategies.

Key Points

  • CAR-T therapy enhanced progression-free survival in large B-cell lymphoma by deploying PD-1 blockade, improving outcomes.
  • Single-cell RNA sequencing identified key changes in CAR-T cells indicating increased persistence in the tumor microenvironment.
  • The study involved a phase I trial evaluating combined PD-1 blockade with novel CAR-T therapy in patients with advanced lymphoma.
  • Results suggest a new multi-target immunotherapy model for overcoming limitations in traditional CAR-T therapy.

Cite This Study

Sheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d65dhttps://doi.org/10.1182/blood-2025-1929
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation2025
  2. 2CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  3. 3Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy2025
  4. 4Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025
  5. 5Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025